Frontlight ResearchEarly access
WithdrawnPhase 1/2
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
Key facts
- Who runs it
- Kunming Hope of Health Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- 1 Oct 2022
- Ended
- 31 Oct 2024
- Type of study
- Interventional
- Treatments tested
- U-CAR-T Cells (LstCAR019)
- Record updated
- 30 November 2022
- Why it stopped
- The PI decides to stop.
Who can take part
- Age
- 2 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (27)Hide the full registry criteria
Who can take part
- Male or female, aged 2-75 years
- A definite diagnosis of relapsed/refractory B-ALL and a percentage of primitive/naive lymphocytes >5% in bone marrow at baseline (flow cytometry)
- CD19 expression was positive in bone marrow or peripheral blood tumor cells
- ECOG score 0-2 points
- Expected survival time ≥3 months
- Adequate liver, kidney, heart and lung function
- Patients who have recovered from acute toxic effects of prior chemotherapy should be excluded from the trial at least one week apart
- Women of childbearing age have negative blood pregnancy test before the start of the trial, and agree to take effective contraceptive measures during the trial until the last follow-up; male subjects with partners of childbearing potential agree to take effective contraceptive measures during the trial until the last follow-up
- Voluntarily sign the informed consent
Who cannot take part
- Presence of other concurrent active malignancy
- Had grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment
- Had undergone other clinical trials in the 4 weeks prior to participating in this trial
- For patients contraindicated with cyclophosphamide and fludarabine chemotherapy
- Subjects requiring systemic corticosteroid therapy (prednisone ≥5mg/ day or equivalent dose of another corticosteroid) or other immunosuppressive agents within 1 month after LstCAR019 cell reinfusion, except for adverse events
- People with severe mental disorders
- A history of any of the following genetic disorders, such as Fanconi anemia, Schu-Day syndrome, Gerstmann syndrome, or any other known bone marrow failure syndrome
- A history or disease of the central nervous system(CNS), such as seizure disease, cerebrovascular ischemia/bleeding, dementia, cerebellar disease, or any autoimmune disease involving the CNS
- Human immunodeficiency virus (HIV) seropositivity; Hepatitis B surface antigen positive or hepatitis B core antibody positive, and HBV-DNA positive; Patients with hepatitis C (HCV-RNA quantitative test results positive); Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections
- Patients with severe history of allergy or allergic constitution
- A history of autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) leading to end-organ damage or requiring systemic immunosuppressive/systemic disease modulating drugs within the past 2 years
- Had or is suffering from interstitial lung disease (e.g., pneumonia, pulmonary fibrosis)
- Any other condition that the investigator deemed inappropriate for inclusion
- Receiving donor lymphocyte infusion within 6 weeks before enrollment
- Acute GVHD of grade II-IV or extensive chronic GVHD
- The presence of any indwelling catheter or drainage (e.g., percutaneous nephrostomy, indwelling catheter, bile drainage, or pleural/peritoneal/pericardial catheter), except for patients who are permitted to use dedicated central venous catheters
- Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan
- Pregnant and lactating women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of LstCAR019 injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).
The group in the trial
- U-CAR-T Cells (LstCAR019)Treatment being tested
Subjects who meet the enrollment conditions will receive intravenous infusion of U-CAR-T Cells (LstCAR019) after lymphodepletion.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL)
- Record updated
- 30 November 2022